Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pediatr ; 138(6): 949-51, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11391350

RESUMEN

In boys with familial male-limited precocious puberty, an activating mutation of the luteinizing hormone receptor causes Leydig cell hyperplasia, resulting in excess testosterone production. There are no reports of Leydig cell masses in boys with familial male-limited precocious puberty. We describe a 10-year-old boy with familial male-limited precocious puberty who developed Leydig cell nodules.


Asunto(s)
Células Intersticiales del Testículo/patología , Pubertad Precoz/genética , Pubertad Precoz/patología , Niño , Humanos , Hiperplasia , Masculino , Pubertad Precoz/metabolismo , Testículo/diagnóstico por imagen , Testosterona/biosíntesis , Ultrasonografía
2.
J Pediatr ; 138(3): 406-10, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11241051

RESUMEN

OBJECTIVE: To evaluate the effect of growth hormone (GH) therapy on pubertal onset, pubertal pace, adult testicular function, and adrenarche in boys with non-GH-deficient short stature. STUDY DESIGN: Randomized, double-blind, placebo-controlled trial. GH (0.074 mg/kg, subcutaneously, 3 times per week) or placebo treatment was initiated in prepubertal or early pubertal boys and continued until near final height was reached (n = 49). Statistical significance was assessed by survival analysis, repeated-measures analysis of variance, and Student t test. RESULTS: GH therapy did not affect the age at pubertal onset, defined either by testicular volume >4 mL or by testosterone concentration >1.0 nmol/L (30 ng/dL). GH treatment also did not affect the pace of puberty, defined either by the rate of change in testicular volume or testosterone concentration during the 4 years after pubertal onset. In boys followed up to age > or =16 years during the study, there were no significant differences in final testicular volume or in plasma testosterone, luteinizing hormone, or follicle-stimulating hormone concentrations. The pace of adrenarche, assessed by change in dehydroepiandrosterone sulfate levels over time, also did not differ significantly between the GH and placebo groups. CONCLUSION: Our findings suggest that GH treatment does not cause testicular damage, alter the onset or pace of puberty, or alter the pace of adrenarche in boys with non-GH-deficient short stature.


Asunto(s)
Enanismo/tratamiento farmacológico , Hormona de Crecimiento Humana/uso terapéutico , Pubertad/efectos de los fármacos , Testículo/efectos de los fármacos , Adolescente , Edad de Inicio , Análisis de Varianza , Niño , Sulfato de Deshidroepiandrosterona/sangre , Método Doble Ciego , Humanos , Masculino , Análisis de Supervivencia , Testosterona/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA